Literature DB >> 11993198

Steroid therapy without primary dose escalation for postthymectomy crisis in 2 thymomatous myasthenia gravis patients.

Masayoshi Inoue1, Kentaro Kimura, Katsuko Hasegawa, Kiyohiro Fujiwara, Katsuhiro Nakagawa, Tsutomu Yasumitsu.   

Abstract

We report 2 cases of thymomatous myasthenia gravis associated with postoperative crisis and medicated with steroid therapy using prednisolone without primary dose escalation. Two women, a 38 years old and the other 64 years old, underwent extended thymectomy under the diagnosis of myasthenia gravis associated with invasive thymoma. Bulbar symptoms in both were severe despite preoperative anticholinesterase medication. Myasthenic crises with an antiacetylcholine receptor antibody (anti-AchR Ab) elevation were encountered in the postoperative clinical course. Daily administrations of a large amount of prednisolone without primary dose escalation and the subsequent tapering therapy effectively improved myasthenic symptoms and decreased their anti-AchR Ab titer. We also discuss difficulties in treatment in these cases.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11993198     DOI: 10.1007/bf02913198

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  10 in total

1.  Intermittent long-term adrenocorticosteroid treatment of myasthenia gravis.

Authors:  N Wakata; Y Kawamura; M Kobayashi; Y Araki; M Kinoshita
Journal:  J Neurol       Date:  1991-02       Impact factor: 4.849

Review 2.  The long-term clinical outcome of myasthenia gravis in patients with thymoma.

Authors:  V Bril; J Kojic; A Dhanani
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

3.  Prognosis of myasthenia gravis: a retrospective study of 380 patients.

Authors:  V Cosi; A Romani; M Lombardi; E Raiola; R Bergamaschi; G Piccolo; A Citterio; C Berzuini
Journal:  J Neurol       Date:  1997-09       Impact factor: 4.849

4.  Benefit from alternate-day prednisone in myasthenia gravis.

Authors:  J R Warmolts; W K Engel
Journal:  N Engl J Med       Date:  1972-01-06       Impact factor: 91.245

5.  Extended thymectomy for myasthenia gravis patients: a 20-year review.

Authors:  A Masaoka; Y Yamakawa; H Niwa; I Fukai; S Kondo; M Kobayashi; Y Fujii; Y Monden
Journal:  Ann Thorac Surg       Date:  1996-09       Impact factor: 4.330

6.  Patterns of acetylcholine receptor antibody fluctuation in myasthenia gravis.

Authors:  M E Seybold; J M Lindstrom
Journal:  Ann N Y Acad Sci       Date:  1981       Impact factor: 5.691

7.  Antibody to acetylcholine receptor in myasthenia gravis: production by lymphocytes from thymus or thymoma.

Authors:  Y Fujii; Y Monden; K Nakahara; J Hashimoto; Y Kawashima
Journal:  Neurology       Date:  1984-09       Impact factor: 9.910

8.  Thymoma-associated myasthenia gravis. Transplantation of thymoma and extrathymomal thymic tissue into SCID mice.

Authors:  S Spuler; A Sarropoulos; A Marx; R Hohlfeld; H Wekerle
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

9.  A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group.

Authors:  J Palace; J Newsom-Davis; B Lecky
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

10.  Long-term cyclosporine treatment in a group of severe myasthenia gravis patients.

Authors:  D M Bonifati; C Angelini
Journal:  J Neurol       Date:  1997-09       Impact factor: 4.849

  10 in total
  1 in total

1.  Postoperative myasthenic crisis successfully treated with immunoadsorption therapy.

Authors:  Junko Ishizeki; Koichi Nishikawa; Fumio Kunimoto; Fumio Goto
Journal:  J Anesth       Date:  2005       Impact factor: 2.078

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.